The report (ToC) provides an overview of the therapies for Multiple Myeloma (Newly diagnosed - NDMM and relapsed/ refractory - RRMM), unmet need, and limitations of the current standard of care (SoC) for relapsed and refractory MM pts. The report highlights the competition and commercial opportunity in pursuing this therapy area - Comprehensive list of the early and late stage drugs in the clinic, their MoA and the companies developing them.
Detailed financial and competitive analysis of the companies leading in this field for this indication - Celgene, Amgen (post-acquisition of Onyx pharma), and MorphoSys are available within this full report. Key M&A activities that have taken place in this area in the last 5 years and a list of products in early /late-stages of development available for in-licensing are highlighted in the report. This report is built using primary and secondary research data and in-house proprietary database.
List Of Tables:
Table 1:COMPETITIVE LANDSCAPE - RRMM
Table 2: DATA COMPARISON - RELAPSED / REFRACTORY MULTIPLE MYELOMA (RRMM),
Table 3 : COMPETITIVE LANDSCAPE - NDMM
Table 5: DATA COMPARISON - RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)
Table 6: PATENT EXPIRIES OF MARKET PRODUCTS , Table 7 LAUNCH TIMELINE AND MARKET POTENTIAL
Table 8 : SELECT M&A AND LICENSING DEALS IN LAST 5 YEARS - 2007 to 2012
Table 9 : SELECT IN-LICENSING OPPORTUNITIES: SMALL MOLECULES & MABS
Table 10 : Amgen - FINANCIAL IMPLICATION OF ONYX ACQUISITION
Table 11 : Amgen - SUM OF THE PARTS VALUATION - POST ONYX ACQUISITION
Table 12 : Amgen, COMPETITIVE LANDSCAPE: ANTI-PCSK9 MAB - HYPERLIPIDEMIA - POOLED ANALYSIS AT ESC 2013
Table 13, Celgene - SUM OF THE PARTS VALUATION
Table 14, Morphosys - NPV VALUATION
Figure 15, Morphosys - TECHNOLOGY PLATFORMS*
Figure 16, Morphosys - PIPELINE IN DEVELOPMENT

To order this report:
Email: [email protected]
US: +1 800 986 6819
UK: +44 203 514 2363
India: +91 22 4098 7600
SOURCE: Researchonglobalmarkets.com

RELATED LINK: